Search

Sepsis is a leading cause of ICU mortality, and early detection is critical for improving patient outcomes. However, existing machine learning models often rely on hourly aggregated data, limiting their ability to capture rapid physiological changes, and frequently lack interpretability, reducing clinical trust and usability. This paper proposes a conceptual framework that integrates Temporal Convolutional Networks (TCNs) with an attention mechanism to analyze high-frequency, minute-level vital sign data for early sepsis prediction. The architecture includes a data input layer, a TCN-based feature extractor with causal dilated convolutions and residual connections, an attention module for identifying clinically relevant time points and variables, and a prediction head that estimates the risk of sepsis within a 6-hour horizon. The proposed approach enables efficient parallel processing, improved temporal sensitivity, and enhanced interpretability compared to recurrent models. While offering advantages in real-time prediction and explainability, challenges remain in handling missing data, ensuring generalizability across ICUs, and minimizing false alarms for clinical deployment.

Acute kidney injury (AKI) is a common and serious condition in critical care, making early prediction essential for timely intervention, reduced mortality, and lower healthcare costs. Machine learning methods using electronic health records have shown promise in identifying at-risk patients, but their performance is often limited by reliance on single-institution datasets and poor generalizability across populations. Privacy regulations such as HIPAA and GDPR further restrict cross-hospital data sharing, hindering the development of more robust models.To address these challenges, this study proposes a federated learning–based framework for AKI prediction, enabling multiple hospitals to collaboratively train models without exchanging raw patient data. Each institution acts as a local client that trains on its own data and shares only model updates, which are aggregated into a global model. The framework incorporates standardized feature processing, secure aggregation, and communication-efficient strategies to ensure scalability across heterogeneous healthcare environments.This privacy-preserving approach improves model generalization by leveraging diverse multi-institutional data while maintaining regulatory compliance. Although it introduces challenges such as communication overhead and convergence complexity, these are mitigated through optimized aggregation methods. Overall, the proposed framework enhances predictive performance, supports clinical decision-making, and offers a scalable foundation for future privacy-aware healthcare AI systems in AKI management.

Polypharmacy, defined as the concurrent use of five or more medications, is highly prevalent among older adults and patients with multiple chronic conditions and is associated with an increased risk of drug–drug interactions (DDIs), leading to adverse drug events, hospitalizations, and higher healthcare costs. Existing DDI databases are often incomplete and fail to capture higher-order interactions, while many machine learning approaches overlook temporal prescription patterns and molecular structure information, limiting their effectiveness in real-world clinical settings. To address these limitations, this study proposes a graph neural network (GNN)-based framework that integrates prescription sequence data with molecular representations to improve DDI prediction. The model constructs a unified graph where drug nodes encode both known interactions and learned similarities, while a prescription sequence encoder captures temporal co-prescribing patterns and a molecular encoder processes SMILES-based structures. These multimodal representations are fused within a patient–drug interaction graph and refined using GNN layers with attention mechanisms to enhance interpretability. By combining longitudinal clinical data with chemical structure information, the framework enables more accurate, context-aware, and patient-specific prediction of DDIs, supports the identification of novel interactions, and improves risk stratification in polypharmacy settings, offering a scalable and interpretable foundation for future clinical decision support systems.